alisertib

Description: Alisertib (also named as MLN8237, MLN-8237) is a novel potent, selective, orally bioavailable Aurora A kinase (AAK) inhibitor with potential antitumor activity. It inhibits Aurora A kinase with an IC50 of 1.2 nM in a cell-free assay and exhibits > 200-fold higher selectivity for Aurora A than Aurora B. Alisertib shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy. Alisertib was developed from its predecessor, MLN8054, in order to minimize the benzodiazepine-like effects seen with MLN8054. The inhibitory effect of Alisertib is ATP-competitive, reversible and AAK-specific with an inhibition constant (Ki) of 0.43 nmol/L. MLN8237 is being investigated to treat advanced cancers.

References: Blood. 2010 Jun 24; 115(25):5202-13; Clin Cancer Res. 2011 Dec 15; 17(24):7614-24; Mol Cancer Ther. 2012 Mar; 11(3):763-74.

Related CAS #: 1208255-63-3 (sodium); 1028486-06-7 (sodium anhydrous)

MLN-8237; alisertib; MLN8237; MLN 8237

Chemical Name: 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4, 5-e]azepin-2-yl)amino)-2-methoxybenzoic acid

SMILES Code: O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC